pharmaceuticals
pharmaceuticals Articles
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
Published:
Last Updated:
As one of the largest pharmaceutical companies on the street, Eli Lilly helps to set the tempo for the industry. Currently the company is in the middle of a very dynamic product launch.
Published:
Last Updated:
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Published:
Last Updated:
Relypsa made a splash in the markets on Thursday morning after the company announced an acquisition agreement.
Published:
Last Updated:
Shares of Progenics Pharmaceuticals and Valeant Pharmaceuticals made handy gains in the market on Wednesday following a key FDA approval that could be a real turning point for the companies.
Published:
Last Updated:
Investors in the biotech and biohealth space generally are taking on much more risk than in the likes of most Dow and S&P 500 stocks. That means they will demand more potential upside for that...
Published:
Last Updated:
Investor reaction to Synergy Pharmaceuticals reaching the FDA mid-cycle review milestone for the plecanatide new drug application in chronic idiopathic constipation was not as positive as the company...
Published:
Last Updated:
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Published:
Last Updated:
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Published:
Last Updated:
Shire made waves Tuesday morning following a key FDA approval of its eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Published:
Last Updated:
Protagonist Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Sage Therapeutics blew out expectations early on Tuesday morning after the company released results from its mid-stage depression trial.
Published:
Last Updated:
Patheon expects to price more than 30 million shares in the range of $19 to $22 per share for a initial public offering valued up to about $771 million.
Published:
Last Updated:
Juno Therapeutics saw its shares sink on Friday after the U.S. Food and Drug Administration levied a clinical hold on its leukemia treatment.
Published:
Last Updated: